The start of 2025 was weaker than market consensus (LSEG) expected.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q1 2025 report, which w...
AVTECH showed solid growth at 33% y/y, meeting Redeye Research estimates (RRe), driven by new contra...
Redeye updates its estimates and valuation following the Q1 2025 report from Safeture.
Redeye is only making some minor adjustments to our forecasts and valuation on the back of Q1 number...
Redeye remains confident on the long-term case despite a major air pocket in the first quarter.
Redeye remains optimistic about Insplorion’s prospects to establish the company as a provider of hig...
Redeye retains its positive view of Vertiseit following a Q1 report where FX and a higher headcount ...
Cost initiatives a success in FWMT... ...and Scandpower continues to excel High competition and pric...
Limited estimate revisions Promising outlook for international expansion Maintain fair value range o...
Q1 disappointed, but likely better from here Orders -33%, sales -13%, EBIT adj.
Q1 NAV -1% vs. ABGSCe Safe Life continues to deliver solid growth Fair value range lowered to SEK 23...
Redeye updates its estimates ahead of Arise’s Q1 report, which is due on 29 April.
Redeye gives its preview on OssDsign’s Q1 2025 report, due on May 6.
Idag, fredag 25 april, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv1 2025.
Redeye comments on Alligator's first quarter 2025, during which a rights issue of gross SEK150m was ...
Redeye provides a short comment on today's order announcement from Scandinavian ChemoTech, this is t...
Redeye returns with a more in-depth take on the Q1 report.
Sales -1% and adj. EBIT -18% vs. ABGSCe Operating cash flow significantly better than expected Likel...
